TET2 and acute myeloid leukemia: Sites associated with TET2 mutations in our replication analysis did not overlap with the 12 CpGs associated with TET2 mutations in the AML patients but did show greater than-expected overlap with the 26,016 sites nominally associated (P < 0.05) with TET2 mutations in AML (OR = 6.7, P < 2 × 10−16).